絞り込み

16404

広告

目標上積みの「タラノア対話」合意 (毎日新聞)

[PR] 温室ガス削減 「パリ協定」控え18年の1年間かけ実施へ 【ボン五十嵐和大】ドイツのボンで開催中の国連気候変動枠組み条約第23回締約国会議(COP23)...

  1. ドイツの温暖化会議で決議採択 - 福井新...
  2. 国内初の種類 恐竜の卵の化石を展示 山口...
  3. 温暖化、COP23大筋合意 先進国の削減...
  4. 本人望めば蘇生中止 消防庁委託研究班提言...

ニュース一覧

SLAMF7-CAR T-cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes.

著者 Gogishvili T , Danhof S , Prommersberger S , Rydzek J , Schreder M , Brede C , Einsele H , Hudecek M
Blood.2017 Oct 31 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (15view , 0users)

Full Text Sources

SLAMF7 is under intense investigation as a target for immunotherapy in multiple myeloma. Here, we redirected the specificity of T-cells to SLAMF7 through expression of a chimeric antigen receptor (CAR) derived from the huLuc63 antibody (Elotuzumab), and demonstrate that SLAMF7-CAR T-cells prepared from patients and healthy donors confer potent antimyeloma reactivity. We confirmed uniform, high-level expression of SLAMF7 on malignant plasma cells in previously untreated and in relapsed/refractory (R/R) myeloma patients who had received prior treatment with proteasome-inhibitors and immunomodulatory agents (IMiDs). Consequently, SLAMF7-CAR T-cells conferred rapid cytolysis of previously untreated and R/R primary myeloma cells in vitro Further, a single administration of SLAMF7-CAR T-cells led to resolution of medullary and extramedullary myeloma manifestations in a murine xenograft model in vivo SLAMF7 is expressed on a fraction of normal lymphocytes, including subsets of NK-cells, T-cells and B-cells. Following modification with the SLAMF7-CAR, both CD8(+) and CD4(+) T-cells rapidly acquired and maintained a SLAMF7(-) phenotype, and could be readily expanded to therapeutically relevant cell doses. We analyzed recognition of normal lymophocytes by SLAMF7-CAR T-cells and show that they induce selective fratricide of SLAMF7(+/high) NK-cells, CD4(+) and CD8(+) T-cells and B-cells. Importantly however, the fratricide conferred by SLAMF7-CAR T-cells spares the SLAMF7(-/low) fraction in each cell subset and preserves functional lymphocytes, including virus-specific T-cells. In aggregate, our data illustrate the potential to utilize SLAMF7-CAR T-cell therapy as an effective treatment against multiple myeloma and provide novel insights into the consequences of targeting SLAMF7 for the normal lymphocyte compartment.
PMID: 29089311 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード